Premium
Haematologic effects of granulocyte‐macrophage colony stimulating factor in a patient with thiamazole‐induced agranulocytosis
Author(s) -
BJÖRKHOLM M.,
PISA P.,
ARVER S.,
BERAN M.
Publication year - 1992
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1992.tb00612.x
Subject(s) - medicine , neutropenia , granulocyte macrophage colony stimulating factor , bone marrow , granulocyte , haematopoiesis , granulocyte colony stimulating factor , adverse effect , hematopoietic growth factor , chemotherapy , leukopenia , immunology , gastroenterology , cytokine , stem cell , biology , genetics
A 61‐year‐old female patient, treated for hyperthyroidism with thiamazole, developed a severe maturation arrest in the granulocytic lineage and a total agranulocytosis. Subcutaneous GM‐CSF was started immediately and given for 6 days. Bone marrow samples were taken before GM‐CSF therapy and on days 3 and 8. An increased number of colonies per 10 5 bone marrow cells documented before institution of GM‐CSF treatment was followed by a gradual decline to normal values. An increase of granulocyte count to > 0.5 times 10 9 l −1 was recorded on the 4th day of treatment and was preceded by an increase in the number of immature granulocyte precursors in the bone marrow on day 3. The patient was discharged on day 8 and experienced no adverse effects of GM‐CSF treatment. Haematopoietic growth factor therapy has a place in the management of patients with drug induced neutropenia/agranulocytosis, which should be further delineated by prospective studies.